

# HMR code: 25-018

<b>Submission date</b> 24/06/2026	<b>Recruitment status</b> Not yet recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 29/06/2026	<b>Overall study status</b> Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 29/06/2026	<b>Condition category</b> Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

## Contact information

### Type(s)

Public, Scientific

### Contact name

None Global Regulatory

### Contact details

Silence Therapeutics Plc., 12 Hammersmith Grove  
London  
United Kingdom  
W6 7AP  
N/A  
[global-regulatory@silence-therapeutics.com](mailto:global-regulatory@silence-therapeutics.com)

### Type(s)

Principal investigator

### Contact name

Dr Takahiro Yamamoto

### ORCID ID

<https://orcid.org/0000-0001-9121-0836>

### Contact details

Hammersmith Medicines Research (HMR), Cumberland Avenue, Park Royal  
London  
United Kingdom  
NW10 7EW

+44 (0)20 8961 4130  
rec@hmrlondon.com

## **Additional identifiers**

**Integrated Research Application System (IRAS)**  
1013877

**CRO trial code**  
25-018

## **Study information**

**Scientific Title**  
HMR code: 25-018 [Full scientific title to be added on or before the deferral expiry date]

**Study objectives**  
This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

**Ethics approval required**  
Ethics approval required

**Ethics approval(s)**  
Approved 18/06/2026, London – Harrow Research Ethics Committee (2 Redman Place, Stratford, London, E20 1JQ, United Kingdom; +44 (0)207 104 8345; harrow.rec@hra.nhs.uk), ref: 26/LO/0232

**Primary study design**  
Interventional

**Allocation**  
Non-randomized controlled trial

**Masking**  
Open (masking not used)

**Control**  
Active

**Assignment**  
Parallel

**Purpose**  
Phase I trial in healthy participants

**Study type(s)**

**Health condition(s) or problem(s) studied**  
Healthy volunteers

## **Interventions**

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

## **Intervention Type**

Drug

## **Phase**

Phase I

## **Drug/device/biological/vaccine name(s)**

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

## **Primary outcome(s)**

1. [Outcome name] measured using [Metric or method of measurement] at [Timepoint(s)]. This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

## **Key secondary outcome(s)**

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

## **Completion date**

16/12/2026

# **Eligibility**

## **Key inclusion criteria**

Healthy human volunteers

## **Healthy volunteers allowed**

Yes

## **Age group**

Mixed

## **Lower age limit**

18 Years

## **Upper age limit**

65 Years

## **Sex**

All

## **Total final enrolment**

0

### **Key exclusion criteria**

This is a phase I trial in healthy volunteers only and qualifies for an automatic deferral. The full details will be added to the trial record on or before the deferral expiry date.

### **Date of first enrolment**

01/07/2026

### **Date of final enrolment**

21/07/2026

## **Locations**

### **Countries of recruitment**

United Kingdom

England

### **Study participating centre**

**Hammersmith Medicines Research (HMR)**

Cumberland Avenue, Park Royal

London

England

NW10 7EW

## **Sponsor information**

### **Organisation**

Silence Therapeutics (United Kingdom)

### **ROR**

<https://ror.org/03p3e4237>

## **Funder(s)**

### **Funder type**

### **Funder Name**

Silence Therapeutics

### **Alternative Name(s)**

Silence Therapeutics plc

**Funding Body Type**

Government organisation

**Funding Body Subtype**

For-profit companies (industry)

**Location**

United Kingdom

## **Results and Publications**

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not expected to be made available